| Issue |
Section |
Title |
File |
| Vol 93, No 4 (2021) |
Original articles |
Analysis of the effectiveness of multiple myeloma treatment based on the clinical experience of European countries |
(Rus)
|
| Vol 93, No 7 (2021) |
Original articles |
Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice |
(Rus)
|
| Vol 93, No 7 (2021) |
Original articles |
Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience |
(Rus)
|
| Vol 93, No 11 (2021) |
Original articles |
The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial |
(Rus)
|
| Vol 94, No 7 (2022) |
Original articles |
Multiple myeloma: response to treatment and survival of patients according to the interim analysis of the Russian observational, retrospective-prospective, multicenter cohort study (MULTISPECT) |
(Rus)
|
| Vol 96, No 12 (2024): Vario (various) |
Original articles |
Isatuximab, pomalidomide and dexamethasone in the treatment of relapsed/refractory multiple myeloma in real clinical practice |
(Rus)
|
| Vol 96, No 12 (2024): Vario (various) |
Original articles |
Safety of sipavibart as a pre-exposure prophylaxis for COVID-19 in individuals at high risk of developing severe disease: results of the NOVELLA clinical study conducted in the Russian population |
(Rus)
|
| Vol 98, No 1 (2026): Outpatient care issues and organization of medical care |
Original articles |
Characteristics and 5-year outcomes in patients with chronic lymphocytic leukemia receiving ibrutinib (a real-world study) |
(Rus)
|
